Related Experiment Video

Updated: Sep 5, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.9K

Current Effective Therapeutics in Management of COVID-19

Kavya Atluri1, Iris Aimlin2, Shitij Arora3

  • 1Department of Bioinformatics, University of California, Los Angeles, CA 90095, USA.

Journal of Clinical Medicine
|July 9, 2022
PubMed

Insights

This review details effective Coronavirus Disease 2019 (COVID-19) therapeutics for outpatient and inpatient management. It examines treatment efficacy against emerging SARS-CoV-2 variants, excluding vaccines.

Area of Science:

  • Virology
  • Infectious Diseases
  • Pharmacology

Background:

  • The SARS-CoV-2 pandemic has caused significant global health and economic damage.
  • Effective therapeutics are crucial for managing Coronavirus Disease 2019 (COVID-19).
  • Understanding treatment efficacy against evolving viral variants is essential.

Purpose of the Study:

  • To review pivotal trial evidence supporting approved COVID-19 therapeutics.
  • To categorize treatments into outpatient and inpatient management strategies.
  • To contextualize therapeutic efficacy concerning SARS-CoV-2 variants.

Main Methods:

  • Literature review of pivotal clinical trials for COVID-19 therapeutics.
  • Categorization of treatments based on patient setting (outpatient/inpatient).
  • Analysis of therapeutic effectiveness in relation to emerging SARS-CoV-2 variants.

Main Results:

  • Several therapeutics have demonstrated efficacy in treating COVID-19.
  • Distinct management strategies exist for outpatient and inpatient settings.
  • Therapeutic effectiveness may vary with emerging SARS-CoV-2 variants.

Conclusions:

  • Approved therapeutics offer valuable options for COVID-19 treatment.
  • Tailoring treatment strategies to patient setting and viral variants is important.
  • Ongoing evaluation of therapeutics against new variants is necessary.
Keywords:
AnakinraCOVID-19Casirivimab plus imdevimabSotrovimabanticoagulationbaricitinibbebtelovimabcoronavirus disease 2019corticosteroidsevusheldmolnupiravirmonoclonal antibodiesomicronpaxlovidremdesivirtherapeuticstimelinetocilizumab

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.4K
Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles10:16

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles

Published on: August 17, 2022

3.4K

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
290
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
305
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
438